Compare AbCellera Biologics Inc (ABCL) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs H2O America — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while H2O America trades at $61.63 (market cap $2.58B). The key difference: AbCellera Biologics Inc and H2O America are close in size by market cap, and H2O America pays a 2.85% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HTO | |
|---|---|---|
Market Cap | $2.35B | $2.58B |
Sector | Health | Technology |
52-Week High | $8.12 | $62.42 |
52-Week Low | $2.78 | $44.44 |
Enterprise Value | $1.99B | $4.31B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
HTO trades at $61.21, down 1.94% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $61.33. The company reported Q1 2026 EPS of $0.50, beating expectations, and maintains strong fundamentals with a 12.87% net income margin. Recent news highlights executive appointments and institutional investments, reinforcing positive sentiment.
The stock presents a balanced opportunity with steady earnings growth and a reliable dividend, but faces risks from high RSI levels indicating overbought conditions and substantial capital expenditures. Analyst consensus is strongly bullish with 80% buy ratings, though investors should monitor execution of growth initiatives and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
